Clinical Trial Update: Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial for metastatic castration-resistant prostate cancer conducted by Amgen has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Snippet

Sponsor: Amgen | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED